Nuvectis gains global rights outside select Asian markets for oncology and complement disease therapies, with Haisco eligible for milestone payments and royalties
The company gets access to Lonza’s clinically validated SYNtecan linker-payload platform as it prepares an IND filing for its acute myeloid leukemia therapy in 2027
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
The agreement targets a long-standing technical hurdle in the field: maintaining chemical purity as RNA constructs extend beyond 100 nucleotides
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
This license is a key regulatory milestone in advancing Hester's prevention-led poultry healthcare portfolio
Subscribe To Our Newsletter & Stay Updated
